New antiviral therapies for chronic hepatitis C - Wikidata - awgldk - TriplyDB

New antiviral therapies for chronic hepatitis C

New antiviral therapies for chronic hepatitis C

http://www.wikidata.org/entity/Q34130399

about

Suppression of La antigen exerts potential antiviral effects against hepatitis A virus Strategies to reduce hepatitis C virus recurrence after liver transplantation Nitazoxanide for chronic hepatitis C Sofosbuvir treatment and hepatitis C virus infection Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus Roles of lipoprotein receptors in the entry of hepatitis C virus Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries New treatments for genotype 1 chronic hepatitis C - focus on simeprevir Antiviral therapies for chronic hepatitis C virus infection with cirrhosis Platelet count and sustained virological response in hepatitis C treatment.Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C.Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response.Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients.Contradictory immune response in post liver transplantation hepatitis B and C.Hepatitis C virus NS5A inhibitors and drug resistance mutations.Hepatitis C virus nonstructural protein 5A inhibits thapsigargin-induced apoptosis.Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region.No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV "Test, Listen, Cure" (TLC) Hepatitis C Community Awareness Campaign.Natural interferon-beta treatment for patients with chronic hepatitis C in Japan Hepatitis C Virus Nonstructural Protein 5A Inhibits MG132-Induced Apoptosis of Hepatocytes in Line with NF-κB-Nuclear Translocation Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.Current management of patients with hepatocellular carcinoma.Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype.Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection.Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report.Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1.Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.Peginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy.Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan Hepatitis C virus infection, microRNA and liver disease progression Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin.IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase.Alanine aminotransferase normalization at week 8 predicts viral response during hepatitis C treatment.Discrepancy between Hepatitis C Virus Genotypes and NS4-Based Serotypes: Association with Their Subgenomic Sequences.Faldaprevir for the treatment of hepatitis C.

P2860

Q21131991-6B2446CA-75EB-419B-A5ED-2DB8813BE0F8 Q22305418-24F0A537-9666-4B8E-953B-938FF720BEAC Q24197485-58F2101A-51E0-4B44-BDE8-58D7E1735847 Q26770024-5FD34E06-1261-4E09-93A9-AF6644AE62B0 Q26775640-AA63A391-D4D3-4286-B6D4-ABFFC0135551 Q26777338-0AA5436E-F967-469F-A09D-F193C13F0B59 Q26781890-54339039-F2C4-40C3-9A85-EC74378F6BB4 Q26853138-C7868CF5-8A87-4D39-B2F0-DF21AE262F59 Q27022794-F75712CF-BD4F-4972-A386-1A18FA3A6E37 Q33407719-33C50AC6-66CB-4B63-B776-AEF77E6D6111 Q33582596-FC0AA3D1-4F0F-41FF-B4E1-235C713F1C37 Q33948241-9D4E8D88-D8C0-4A6B-9ACA-974830533FA9 Q34007851-0036D55F-3B9F-41F5-8CCD-E5D19FD25FC7 Q34103218-BD571AFA-537F-4FD2-B0EF-FC7CBA3A50F9 Q34152074-AC0CF1E2-4DF8-4E33-8378-859F1CCA8C09 Q34411617-7E1DFA78-C14A-4337-A6D7-359E4543C3C7 Q34542590-E35555C7-3B95-44DC-A818-59F4DB0A3B76 Q34998753-2B452B16-3E3A-47A3-9121-70F7827F63B3 Q35069533-80549246-B5A8-4187-9BDC-F563B97BAB72 Q35127108-0998E58B-90A1-42C5-B00B-DD5CAA509905 Q35668734-D6CAD196-AD3A-4B3C-9E97-44E5FAD04470 Q35680404-5F805A71-485F-4565-99C4-6AB01B914C12 Q35867385-4D579C49-787D-4F30-8510-CC277A4A38BF Q35895363-B149AEE5-283D-416C-8103-92573E7BB997 Q35903139-0B8C1ED2-16E8-4752-A961-F2C232732BDB Q35905985-BF96291E-80C8-43F2-B95D-15D215986BEE Q35947900-74366224-5F37-4AC9-AC51-AA4C29B6F363 Q36073283-57810D1F-2289-4BD9-A53D-453F43BAA703 Q36148043-79CC32E5-90F4-4341-977C-6E148494750F Q36246785-FC28AB09-7685-4C89-A5E4-02DC5B796AF8 Q36501509-E599DD6E-CA27-4661-BB65-2A14CE951459 Q36792338-48E6743F-A668-4738-A6F4-AA62E4779684 Q36953126-C3C51F86-5864-4DC1-9A14-6E59684645E4 Q36970046-8FACD1AA-E558-4CE9-90EA-BA77B559F037 Q37196517-6CFF9D9C-1FC7-4DC8-969C-701160361F50 Q37298739-8114FBA3-1581-448D-9CDC-F09C860B17C8 Q37358287-4A90FAFD-4101-40F6-9470-49780DAF2763 Q37408864-7B9E62F7-10BA-4AD3-BAAD-EA84C31BA0D4 Q37631645-389C8B63-719D-4143-9326-34A8B4F1F590 Q38370056-EAE16D52-8AAA-4351-B449-4C964666677C

P2860

New antiviral therapies for chronic hepatitis C

http://www.wikidata.org/entity/Q34130399

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

New antiviral therapies for chronic hepatitis C

@ast

New antiviral therapies for chronic hepatitis C

@en

New antiviral therapies for chronic hepatitis C

@nl

type

label

New antiviral therapies for chronic hepatitis C

@ast

New antiviral therapies for chronic hepatitis C

@en

New antiviral therapies for chronic hepatitis C

@nl

prefLabel

New antiviral therapies for chronic hepatitis C

@ast

New antiviral therapies for chronic hepatitis C

@en

New antiviral therapies for chronic hepatitis C

@nl

P1433

Q34130399-324629E5-DF84-4ED3-94B8-4BDA3644C93D

P1476

Q34130399-034A3D42-1F76-4770-8CE6-86E81AACF522

P2093

Q34130399-1F35C1C4-1D05-4DD7-BE63-8E69E59F408D

Q34130399-2AD8BAA6-B4E4-4E1D-846E-E169676B34E8

Q34130399-A4C67C4E-740A-4F66-B89D-20E1261CE3E5

P2860

Q34130399-04B9CDF2-D5A5-4FB8-8E43-76EA38972E17

Q34130399-0599794F-C63A-465B-A4E3-DCE1405F6783

Q34130399-068BDAE2-8089-4FD7-A5EA-25FBD906EB07

Q34130399-07EA26E0-56A5-4633-B425-8BC1D6CD443B

Q34130399-0A9DD942-13E5-4D2D-B66C-D6D922479DBE

Q34130399-18A5DFFF-8687-4F46-B57F-75D8868A900D

Q34130399-1921B22E-6657-40EC-AF8C-41EC129FF684

Q34130399-1A36697E-5FF8-4C55-8E69-905DDFD13C26

Q34130399-1AAB9237-F481-4B09-81D7-29B8C3B5F21A

Q34130399-1AD5120D-350A-442B-B2BB-7383DC147E96

P2888

Q34130399-96DB7B70-48C2-4822-8726-F6B9FBAF2084

P304

Q34130399-BC321F8E-63C3-4FC7-B781-F5C11B564972

P31

Q34130399-AC1DDE62-7ACC-41B7-B55A-D0EB11D26710

P356

Q34130399-2579F7F7-CD06-46B4-8262-D5107E593CC3

P433

Q34130399-E116A24C-6432-4D11-BC55-45D327AF17D0

P478

Q34130399-1EBF1051-BE38-4896-AB12-02621AAB9431

P577

Q34130399-936AB3C9-3F86-48D2-A371-9945AE0D0BD3

P5875

Q34130399-CF05653E-B71A-4120-97E2-AEED46E31DAC

P6179

Q34130399-F0EAD33E-C9FE-4294-89C6-881D7F8E07D9

P698

Q34130399-CCE5E8D6-439D-4C8F-A1AA-18D70F4209A4

P932

Q34130399-C3C1AB7C-81C9-44E2-8E90-16738F29A91D

P356

S12072-010-9193-3

P1433

Hepatology international

P1476

New antiviral therapies for chronic hepatitis C

@en

P2093

Fumio Imazeki

http://www.w3.org/2001/XMLSchema#string

Osamu Yokosuka

http://www.w3.org/2001/XMLSchema#string

Tatsuo Kanda

http://www.w3.org/2001/XMLSchema#string

P2860

Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase

Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication

Robust hepatitis C virus infection in vitro.

Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells.

Generation of Infectious Hepatitis C Virus in Immortalized Human Hepatocytes

Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein

Small Interfering RNA Targeted to Hepatitis C Virus 5' Nontranslated Region Exerts Potent Antiviral Effect

Sulfated Homologues of Heparin Inhibit Hepatitis C Virus Entry into Mammalian Cells

Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2

Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

P2888

s12072-010-9193-3

P304

548-561

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12072-010-9193-3

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47729887

http://www.w3.org/2001/XMLSchema#string

P6179

1029331907

http://www.w3.org/2001/XMLSchema#string

P698

21063477

http://www.w3.org/2001/XMLSchema#string

P932

2940000

http://www.w3.org/2001/XMLSchema#string